Literature DB >> 32088872

Peptide Nucleic Acids for MicroRNA Targeting.

Roberto Gambari1, Jessica Gasparello2, Enrica Fabbri2, Monica Borgatti2, Anna Tamanini3, Alessia Finotti2.   

Abstract

The involvement of microRNAs in human pathologies is firmly established. Accordingly, the pharmacological modulation of microRNA activity appears to be a very interesting approach in the development of new types of drugs (miRNA therapeutics). One important research area is the possible development of miRNA therapeutics in the field of rare diseases. In this respect, appealing molecules are based on peptide nucleic acids (PNAs), displaying, in their first description, a pseudo-peptide backbone composed of N-(2-aminoethyl)glycine units, and found to be excellent candidates for antisense and antigene therapies. The aim of the present article is to describe methods for determining the activity of PNAs designed to target microRNAs involved in cystic fibrosis, using as model system miR-145-5p and its target cystic fibrosis transmembrane conductance regulator (CFTR) mRNA. The methods employed to study the effects of PNAs targeting miR-145-5p are presented here by discussing data obtained using as cellular model system the human lung epithelial Calu-3 cell line.

Entities:  

Keywords:  Cystic fibrosis; MiRNA therapeutics; MicroRNA; Peptide nucleic acids

Mesh:

Substances:

Year:  2020        PMID: 32088872     DOI: 10.1007/978-1-0716-0243-0_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Differential effects on the miRNome of the treatment of human airway epithelial Calu-3 cells with peptide-nucleic acids (PNAs) targeting microRNAs miR-101-3p and miR-145-5p: Next generation sequencing datasets.

Authors:  Jessica Gasparello; Enrica Fabbri; Roberto Gambari; Alessia Finotti
Journal:  Data Brief       Date:  2021-01-09

Review 2.  Multifunctional Delivery Systems for Peptide Nucleic Acids.

Authors:  Stefano Volpi; Umberto Cancelli; Martina Neri; Roberto Corradini
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-25

3.  Combined Treatment of Bronchial Epithelial Calu-3 Cells with Peptide Nucleic Acids Targeting miR-145-5p and miR-101-3p: Synergistic Enhancement of the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene.

Authors:  Chiara Papi; Jessica Gasparello; Matteo Zurlo; Alex Manicardi; Roberto Corradini; Giulio Cabrini; Roberto Gambari; Alessia Finotti
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.